Voyager Therapeutics(VYGR) - 2024 Q2 - Quarterly Results

EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results – Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease – – Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate – – Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chi ...